Study effect of IL-35 and some sex hormones in male patients who have multiple sclerosis (MS)

Authors

  • Ali K. Bidan University of Baghdad
  • Nisreen A. Hamzah

DOI:

https://doi.org/10.14419/ijac.v3i1.4666

Keywords:

Multiple Sclerosis, Interleukin-35, Testosterone, Progesterone, Prolactin.

Abstract

Multiple sclerosis (MS) is a disease characterized by inflammation and demyelination. Currently, the cause of MS is unknown. An early and accurate diagnosis of multiple sclerosis (MS) is very important, since it allows early treatment initiation, which reduces the activity of the disease. The present study aimed to focus a light on the contribution of interlukin-35 (IL-35) and its relation to some hormones such as testosterone, progesterone, and prolactin (PRL) in the pathogenesis of multiple sclerosis. Twenty two enrollers (samples) attended from Teaching hospital of Baghdad were divided into two groups. Ten enrollers were described as healthy subject as control group as group 1 (G1) in range ages (20-30) years. Twelve male patients as group 2 (2) have been relapsing remitting multiple sclerosis (RRMS) matched in age with group 1 (G1).

References

[1] Francisco PG, Andrew JS, & Colin RY, (2013), Hormone and immune system interactions in demyelinating disease., Journal of Hormones and Behavior, 63, pp 315-321. http://dx.doi.org/10.1016/j.yhbeh.2012.10.014.

[2] Codarri, L, Fontana A, & Becher, B, (2010), Cytokine networks in multiple sclerosis: lost in translation, Journal of Current Opinion Neurology, 23, pp 205–211. http://dx.doi.org/10.1097/WCO.0b013e3283391feb.

[3] María, C S, John T, Carlos P, & Mercedes V, (2012), Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. Journal of Neuroimmunology, 247, pp 86-94. http://dx.doi.org/10.1016/j.jneuroim.2012.03.020.

[4] Benjamen W, Richard N, & Omar M, (2012) Multiple Sclerosis, Journal of Medicine, 40, pp 523-528. http://dx.doi.org/10.1016/j.mpmed.2012.07.007.

[5] Marcus W, Luanne M, Smriti M A, & Young W, (2013), Environmental factors and their regulation of immunity in multiple sclerosis, Journal of Neurological Science, 324,(1-2): pp10-16. http://dx.doi.org/10.1016/j.jns.2012.10.021.

[6] Mattson D, Petrie M, & Srivastava D K, (1995) ,Multiple Sclerosis: Sexual dysfunction and its responses to medications, Journal of Arch Neurology, 52,(9): pp 862-868. http://dx.doi.org/10.1001/archneur.1995.00540330040012.

[7] Goodman A D, Brown T R, & Krupp L B, (2009), Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial, Journal of Lancet ,373, pp732-738. http://dx.doi.org/10.1016/S0140-6736(09)60442-6.

[8] Thualfeqar G M, (2010), Relevance of Sex Hormones Levels with Serum Lipid Profile and Oxidative Stress in Infertile Men'', M.Sc thesis, Dept of chemistry., Al-Nahrain Univ, pp 11-12.

[9] Agostino D P, Milano S, Barbera C, & Di Bella G, (1999), Sex hormones modulate inflammatory mediators produced by macrophages, Journal of .Annals New York Academic Science, 876, pp 426-429. http://dx.doi.org/10.1111/j.1749-6632.1999.tb07667.x.

[10] Danis V A, Brooks P M, & Li ZG, (1993), Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro, Journal of Clininical Expermental Rheumatology, 11,(2): pp157-162.

[11] Liva S M, & Voskuhl R R, (2001), Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production, Journal of Immunology, 167, (4): pp 2060-2067. http://dx.doi.org/10.4049/jimmunol.167.4.2060.

[12] Whitacre C C , Reingold S C, & O'Loony P A, (1999), A gender gap in autoimmunity, Journal of Science, 283,(5406): pp1277-7218. http://dx.doi.org/10.1126/science.283.5406.1277.

[13] Judy G, (2010), "Managing Multiple Sclerosis Naturally. Self-help. Guide to living with MS", Healing Arts Press, USA, pp.217-218.

[14] Chikanza, I C, (1999), 'Prolactin and neuroimmunomodulation: in vitro and in vivo observations,m Journal of Annals New York Academic Science, 876, pp119–130.

[15] Grattan DR, & Kokay IC, (2008), Prolactin: a pleiotropic neuroendocrine hormone, Journal of Neuroendocrinol, 20, (6): pp 752–763. http://dx.doi.org/10.1111/j.1365-2826.2008.01736.x.

[16] Li X, Mai J, Virtue A, Yin Y, Gong R, (2012), IL-35 is a novel responsive anti-inflammatory cytokine–a new system of categorizing anti-inflammatory cytokines, Journal of. PLoS ONE 7, (3): Article ID e33628. http://dx.doi.org/10.1371/journal.pone.0033628.

[17] Chaturvedi V, Collison L W, Guy C S, and Workman C J, & Vignali D A, (2011), Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance, Journal of. Immunology, 186, pp 6661–6666. http://dx.doi.org/10.4049/jimmunol.1100315.

[18] Lauren W C , Vandana C , Abigail L H, & Paul R G, (2010), IL-35-mediated induction of a potent regulatory T cell population, Journal of Nature Immunology, 11, (12): pp 1093-1101. http://dx.doi.org/10.1038/ni.1952.

[19] Stefan M G, & Rhonda R V, (2009), Estrogen and Testosterone Therapies in Multiple Sclerosis, Journal of Progress Brain Research, 175, pp 239–251.

[20] Stein D G, (2008), Progesterone exerts neuroprotective effects after brain injury, Journal of. Brain Reearchs Reviews, 57, (2): pp 386–397. http://dx.doi.org/10.1016/j.brainresrev.2007.06.012.

[21] Tomassini V V, & Pozzilli, C, (2009), Sex hormones, brain damage and clinical course of Multiple Sclerosis, Journal of Neurological Science, 286, pp 35-39. http://dx.doi.org/10.1016/j.jns.2009.04.014.

[22] Shahar S, Mona B, & Hedi O, (2011), Prolactin and autoimmunity, Journal of Autoimmunity Reviews 1186, 6, pp 1-2.

Downloads

Published

2015-05-30

Issue

Section

Articles